Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcellx, Inc. stock logo
ACLX
Arcellx
$65.48
+0.5%
$61.18
$47.86
$107.37
$3.61B0.34604,254 shs480,079 shs
Genmab A/S stock logo
GMAB
Genmab A/S
$21.78
+2.0%
$19.98
$17.24
$28.96
$13.69B0.961.15 million shs1.33 million shs
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$19.56
-5.1%
$23.40
$6.78
$36.91
$14.53B-0.943.63 million shs6.20 million shs
Viatris Inc. stock logo
VTRS
Viatris
$8.59
-1.4%
$8.26
$6.85
$13.55
$10.08B0.910.84 million shs25.51 million shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcellx, Inc. stock logo
ACLX
Arcellx
+5.18%+5.15%-0.63%-5.43%+21.44%
Genmab A/S stock logo
GMAB
Genmab A/S
-1.93%+0.33%-0.61%-11.41%-25.95%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
+16.30%-19.58%-26.09%+5.47%+133.26%
Viatris Inc. stock logo
VTRS
Viatris
+0.40%+1.45%+0.87%-7.96%-17.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcellx, Inc. stock logo
ACLX
Arcellx
2.3216 of 5 stars
3.51.00.00.03.82.50.0
Genmab A/S stock logo
GMAB
Genmab A/S
3.4261 of 5 stars
3.33.00.00.02.60.03.1
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
2.9874 of 5 stars
4.53.00.00.02.01.70.0
Viatris Inc. stock logo
VTRS
Viatris
2.1941 of 5 stars
1.93.02.50.01.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcellx, Inc. stock logo
ACLX
Arcellx
3.07
Buy$111.3370.03% Upside
Genmab A/S stock logo
GMAB
Genmab A/S
2.69
Moderate Buy$39.1779.83% Upside
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
3.09
Buy$37.4091.21% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.75
Reduce$10.5022.24% Upside

Current Analyst Ratings Breakdown

Latest ACLX, GMAB, SMMT, and VTRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$40.00
5/9/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.00
5/8/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/2/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $41.00
4/28/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
4/28/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.00
4/25/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$31.00 ➝ $44.00
4/23/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
4/9/2025
Genmab A/S stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $37.00
4/1/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform
3/26/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Summit Redstone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$35.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcellx, Inc. stock logo
ACLX
Arcellx
$76.81M46.98N/AN/A$9.97 per share6.57
Genmab A/S stock logo
GMAB
Genmab A/S
$3.12B4.48$1.47 per share14.80$8.04 per share2.71
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$700K20,752.21N/AN/A$0.11 per share177.82
Viatris Inc. stock logo
VTRS
Viatris
$14.33B0.70$4.07 per share2.11$17.06 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcellx, Inc. stock logo
ACLX
Arcellx
-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%8/14/2025 (Estimated)
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7612.5212.242.6536.30%16.78%13.79%8/14/2025 (Estimated)
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
$54.70M-$3.17N/A3.34N/A-5.87%16.46%7.09%8/14/2025 (Estimated)

Latest ACLX, GMAB, SMMT, and VTRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million
5/8/2025Q1 2025
Genmab A/S stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.49$0.50+$0.01-$2.55$3.30 billion$3.25 billion
5/1/2025Q1 2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcellx, Inc. stock logo
ACLX
Arcellx
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
$0.485.59%+13.30%N/A N/A

Latest ACLX, GMAB, SMMT, and VTRS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.55%5/23/20255/23/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcellx, Inc. stock logo
ACLX
Arcellx
N/A
4.29
4.29
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/A
8.31
8.31
Viatris Inc. stock logo
VTRS
Viatris
0.82
1.51
0.96

Institutional Ownership

CompanyInstitutional Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
96.03%
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
4.61%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Arcellx, Inc. stock logo
ACLX
Arcellx
8.35%
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
84.90%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcellx, Inc. stock logo
ACLX
Arcellx
8055.11 million50.70 millionOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
1,660641.20 million651.58 millionOptionable
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
110742.67 million86.28 millionOptionable
Viatris Inc. stock logo
VTRS
Viatris
37,0001.17 billion1.19 billionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcellx stock logo

Arcellx NASDAQ:ACLX

$65.48 +0.34 (+0.52%)
As of 04:00 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.78 +0.43 (+2.01%)
As of 04:00 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$19.56 -1.06 (-5.14%)
As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Viatris stock logo

Viatris NASDAQ:VTRS

$8.59 -0.12 (-1.38%)
As of 04:00 PM Eastern

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.